AMPH
Amphastar Pharmaceuticals Inc

1,129
Mkt Cap
$1.45B
Volume
251,521.00
52W High
$39.01
52W Low
$20.39
PE Ratio
11.88
AMPH Fundamentals
Price
$27.00
Prev Close
$26.79
Open
$26.75
50D MA
$25.87
Beta
0.71
Avg. Volume
476,118.42
EPS (Annual)
$3.06
P/B
1.60
Rev/Employee
$360,930.47
Loading...
Loading...
News
all
press releases
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Consensus Rating of "Hold" from Brokerages
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) has earned a consensus recommendation of "Hold" from the eight research firms that are presently covering the company, MarketBeat.com...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
129,339 Shares in Amphastar Pharmaceuticals, Inc. $AMPH Purchased by Rice Hall James & Associates LLC
Rice Hall James & Associates LLC acquired a new position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) during the 3rd quarter, according to the company in its most recent disclosure...
MarketBeat·3d ago
News Placeholder
Can CorMedix's Melinta Acquisition Aid Growth Beyond DefenCath?
CRMD's $300M Melinta acquisition adds seven products and helps raise 2025 revenue guidance, but questions remain over easing DefenCath reliance.
Zacks·4d ago
News Placeholder
Squarepoint Ops LLC Lowers Stock Position in Amphastar Pharmaceuticals, Inc. $AMPH
Squarepoint Ops LLC cut its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 67.0% during the second quarter, according to the company in its most recent...
MarketBeat·6d ago
News Placeholder
Insider Selling: Amphastar Pharmaceuticals (NASDAQ:AMPH) EVP Sells 9,787 Shares of Stock
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) EVP Rong Zhou sold 9,787 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Wednesday, December 17th. The...
MarketBeat·12d ago
News Placeholder
CRMD Up More Than 40% YTD: Time to Buy, Sell or Hold the Stock?
CorMedix surges on strong DefenCath uptake as sales climb while the Melinta acquisition expands and diversifies its commercial portfolio.
Zacks·19d ago
News Placeholder
Amphastar Pharmaceuticals (NASDAQ:AMPH) Upgraded to "Hold" at Barclays
Barclays upgraded Amphastar Pharmaceuticals to a "hold" rating in a research report on Monday...
MarketBeat·21d ago
News Placeholder
Amphastar Pharmaceuticals (NASDAQ:AMPH) Coverage Initiated by Analysts at Barclays
Barclays initiated coverage on Amphastar Pharmaceuticals in a research note on Tuesday. They set an "equal weight" rating and a $30.00 target price for the company...
MarketBeat·21d ago
News Placeholder
Marshall Wace LLP Sells 183,037 Shares of Amphastar Pharmaceuticals, Inc. $AMPH
Marshall Wace LLP decreased its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 17.7% in the 2nd quarter, according to the company in its most recent filing with the...
MarketBeat·22d ago
News Placeholder
Amphastar Pharmaceuticals, Inc. $AMPH Shares Bought by Quantbot Technologies LP
Quantbot Technologies LP increased its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 188.8% during the second quarter, according to the company in its most recent 13F...
MarketBeat·23d ago
<
1
2
...
>

Latest AMPH News

View

Advertisement|Remove ads.

Advertisement|Remove ads.